MDL | - |
---|---|
Molecular Weight | 376.86 |
Molecular Formula | C19H22ClFN4O |
SMILES | O=C(C(N=C1)=CN1C)N(CC(C=C2)=CC(Cl)=C2F)C[C@@H]3[C@](C4)([H])[C@@]3([H])CN4C |
PF-03463275 (1-10 mg/kg; s.c.) attenuates oscillatory potentials (OPs) [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Male Sprague-Dawley rats [2] |
Dosage: | 1, 3 and 10 mg/kg |
Administration: | S.c. |
Result: | A dose-dependent reduction in the amplitude of oscillatory potentials (OPs) elicited from the dark-adapted rats. |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT01159626 | Pfizer |
Healthy
|
July 2010 | Phase 1 |
NCT01911676 | Yale University |
Cognitive Impairments Associated With Schizophrenia
|
August 2013 | Phase 2 |
NCT00977522 | Pfizer |
Schizophrenia
|
November 2009 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 33.33 mg/mL ( 88.44 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.6535 mL | 13.2675 mL | 26.5351 mL |
5 mM | 0.5307 mL | 2.6535 mL | 5.3070 mL |
10 mM | 0.2654 mL | 1.3268 mL | 2.6535 mL |